Spots Global Cancer Trial Database for stage iiic esophageal cancer
Every month we try and update this database with for stage iiic esophageal cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer | NCT00274885 | Cancer | oxaliplatin management of t... | 18 Years - | National Cancer Institute (NCI) | |
| S-1, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIA, Stage III, or Stage IVA Esophageal Cancer That Can Be Removed by Surgery | NCT00659113 | Esophageal Canc... | cisplatin tegafur-gimerac... cytology specim... endoscopic biop... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy | NCT01243398 | Adenocarcinoma ... Esophageal Canc... | quality-of-life... | 18 Years - | University of Oxford | |
| Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery | NCT01107639 | Adenocarcinoma ... Esophageal Canc... | cetuximab cisplatin docetaxel adjuvant therap... neoadjuvant the... | 18 Years - 75 Years | Swiss Group for Clinical Cancer Research | |
| Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | NCT00938470 | Adenocarcinoma ... Esophageal Canc... Gastric Cancer | capecitabine docetaxel fluorouracil oxaliplatin radiation thera... therapeutic con... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer | NCT01498289 | Adenocarcinoma ... Esophageal Canc... Gastric Cancer | FOLFOX regimen docetaxel fluorouracil irinotecan hydr... leucovorin calc... oxaliplatin | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | NCT01705340 | Adenocarcinoma ... HER2-positive B... Male Breast Can... Recurrent Breas... Recurrent Esoph... Recurrent Gastr... Stage IIIC Brea... Stage IIIC Esop... Stage IIIC Gast... Stage IV Breast... Stage IV Esopha... Stage IV Gastri... | Akt inhibitor M... trastuzumab lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | NCT01212822 | Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Squamous Cell C... Stage IA Esopha... Stage IA Gastri... Stage IB Esopha... Stage IB Gastri... Stage IIA Esoph... Stage IIA Gastr... Stage IIB Esoph... Stage IIB Gastr... Stage IIIA Esop... Stage IIIA Gast... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Gast... | bevacizumab oxaliplatin leucovorin calc... fluorouracil therapeutic con... laboratory biom... | 18 Years - | Fox Chase Cancer Center | |
| Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer | NCT00978549 | Adenocarcinoma ... Esophageal Canc... Gastric Cancer Nausea and Vomi... Pain | docetaxel steroid therapy questionnaire a... nausea and vomi... pain therapy quality-of-life... standard follow... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer | NCT00861094 | Esophageal Canc... | cisplatin 5-FU oxaliplatin radiation thera... Folinic Acid | 18 Years - | UNICANCER | |
| FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma | NCT02037048 | Adenocarcinoma ... Adenocarcinoma ... Adenocarcinoma ... Stage IIIA Esop... Stage IIIB Esop... Stage IIIC Esop... | oxaliplatin leucovorin calc... fluorouracil therapeutic con... radiation thera... carboplatin paclitaxel | 18 Years - | Case Comprehensive Cancer Center | |
| Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer | NCT00509561 | Esophageal Canc... | cetuximab capecitabine cisplatin radiation thera... | 18 Years - | Wales Cancer Trials Unit | |
| Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery | NCT01612546 | Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Esoph... Recurrent Gastr... Squamous Cell C... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Gast... Stage IV Esopha... Stage IV Gastri... | cyclodextrin-ba... Laboratory biom... Pharmacological... | 18 Years - | City of Hope Medical Center | |
| Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer | NCT00978549 | Adenocarcinoma ... Esophageal Canc... Gastric Cancer Nausea and Vomi... Pain | docetaxel steroid therapy questionnaire a... nausea and vomi... pain therapy quality-of-life... standard follow... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer | NCT01498289 | Adenocarcinoma ... Esophageal Canc... Gastric Cancer | FOLFOX regimen docetaxel fluorouracil irinotecan hydr... leucovorin calc... oxaliplatin | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery | NCT01107639 | Adenocarcinoma ... Esophageal Canc... | cetuximab cisplatin docetaxel adjuvant therap... neoadjuvant the... | 18 Years - 75 Years | Swiss Group for Clinical Cancer Research | |
| C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer | NCT02344810 | Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Gastrointestina... Intestinal Aden... Mixed Adenocarc... Stage IIIA Esop... Stage IIIA Gast... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Gast... Stage IV Esopha... Stage IV Gastri... | c-Met inhibitor... placebo oxaliplatin leucovorin calc... fluorouracil pharmacological... laboratory biom... | 18 Years - | Eastern Cooperative Oncology Group | |
| Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer | NCT00425425 | Esophageal Canc... | cetuximab fluorouracil oxaliplatin conventional su... neoadjuvant the... radiation thera... | 18 Years - 70 Years | Technical University of Munich | |
| Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | NCT01212822 | Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Squamous Cell C... Stage IA Esopha... Stage IA Gastri... Stage IB Esopha... Stage IB Gastri... Stage IIA Esoph... Stage IIA Gastr... Stage IIB Esoph... Stage IIB Gastr... Stage IIIA Esop... Stage IIIA Gast... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Gast... | bevacizumab oxaliplatin leucovorin calc... fluorouracil therapeutic con... laboratory biom... | 18 Years - | Fox Chase Cancer Center | |
| Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer | NCT00655876 | Esophageal Canc... | cetuximab cisplatin paclitaxel radiation thera... | 18 Years - 74 Years | Radiation Therapy Oncology Group | |
| Study of Tissue Samples in Predicting How Well Chemotherapy and Radiation Therapy Will Kill Cancer Cells in Patients With Squamous Cell Carcinoma of the Esophagus | NCT00766480 | Esophageal Canc... | cisplatin fluorouracil radiation thera... | 20 Years - 74 Years | National Cancer Institute (NCI) | |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | NCT01705340 | Adenocarcinoma ... HER2-positive B... Male Breast Can... Recurrent Breas... Recurrent Esoph... Recurrent Gastr... Stage IIIC Brea... Stage IIIC Esop... Stage IIIC Gast... Stage IV Breast... Stage IV Esopha... Stage IV Gastri... | Akt inhibitor M... trastuzumab lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer | NCT00702884 | Esophageal Canc... | sunitinib malat... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer | NCT00861094 | Esophageal Canc... | cisplatin 5-FU oxaliplatin radiation thera... Folinic Acid | 18 Years - | UNICANCER | |
| S-1, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIA, Stage III, or Stage IVA Esophageal Cancer That Can Be Removed by Surgery | NCT00659113 | Esophageal Canc... | cisplatin tegafur-gimerac... cytology specim... endoscopic biop... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | NCT01212822 | Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Squamous Cell C... Stage IA Esopha... Stage IA Gastri... Stage IB Esopha... Stage IB Gastri... Stage IIA Esoph... Stage IIA Gastr... Stage IIB Esoph... Stage IIB Gastr... Stage IIIA Esop... Stage IIIA Gast... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Gast... | bevacizumab oxaliplatin leucovorin calc... fluorouracil therapeutic con... laboratory biom... | 18 Years - | Fox Chase Cancer Center | |
| Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer | NCT00425425 | Esophageal Canc... | cetuximab fluorouracil oxaliplatin conventional su... neoadjuvant the... radiation thera... | 18 Years - 70 Years | Technical University of Munich | |
| Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery | NCT01107639 | Adenocarcinoma ... Esophageal Canc... | cetuximab cisplatin docetaxel adjuvant therap... neoadjuvant the... | 18 Years - 75 Years | Swiss Group for Clinical Cancer Research | |
| Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer | NCT00509561 | Esophageal Canc... | cetuximab capecitabine cisplatin radiation thera... | 18 Years - | Wales Cancer Trials Unit | |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | NCT01705340 | Adenocarcinoma ... HER2-positive B... Male Breast Can... Recurrent Breas... Recurrent Esoph... Recurrent Gastr... Stage IIIC Brea... Stage IIIC Esop... Stage IIIC Gast... Stage IV Breast... Stage IV Esopha... Stage IV Gastri... | Akt inhibitor M... trastuzumab lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
